TECH
Bio-Techne Corp
NASDAQ: TECH · HEALTHCARE · BIOTECHNOLOGY
$72.12
+0.06% today
Updated 2026-09-11
Market cap
$11.34B
P/E ratio
62.34
P/S ratio
9.33x
EPS (TTM)
$1.16
Dividend yield
0.44%
52W range
$43 – $73
Volume
3.3M
WallStSmart proprietary scores
54
out of 100
Grade: C
Hold
Investment rating
6.0
Growth
B9.5
Quality
A+7.0
Profitability
B+5.3
Valuation
C+6/9
Piotroski F-Score
Moderate
3.8
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$70.73
-1.93%
12-Month target
$11.32
-84.30%
Intrinsic (DCF)
$197.11
Margin of safety
+67.81%
0 Strong Buy2 Buy12 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 3.83 — safe zone
+ Free cash flow $86.94M — positive
+ 67.81% below intrinsic value
+ Debt/equity 0.14x — low leverage
Risks
- P/E 62.34x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|
| Revenue | $1.14B | $1.16B | $1.22B | $1.22B | $1.22B |
| Net income | $285.26M | $168.10M | $73.40M | $181.86M | $54.61M |
| EPS | — | — | — | — | $1.16 |
| Free cash flow | $216.15M | $236.10M | $256.55M | $263.22M | $86.94M |
| Profit margin | 25.10% | 14.50% | 6.02% | 14.97% | 15.00% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-08-17 | KELDERMAN, KIM | Buy | 93,582 | — |
| 2026-08-17 | KELDERMAN, KIM | Buy | 57,590 | — |
| 2026-08-17 | HIPPEL, JAMES | Buy | 36,459 | — |
Peer comparison
Smart narrative
Bio-Techne Corp trades at $72.12. representing a P/E of 62.34x trailing earnings. Our Smart Value Score of 54/100 indicates the stock is fair. The company scores 6/9 on the Piotroski F-Score. With an Altman Z-Score of 3.83, it sits in the safe zone. TTM revenue stands at $1.22B. with profit margins at 15.00%. Our DCF model estimates intrinsic value at $197.11.
Frequently asked questions
What is Bio-Techne Corp's stock price?
Bio-Techne Corp (TECH) trades at $72.12, on a P/E of 62.3x and a P/S of 9.3x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Bio-Techne Corp overvalued?
Bio-Techne Corp carries a Smart Value Score of 54/100 (Grade C), which we rate Hold. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $197.11 versus the $72.12 price, a 67.8% margin of safety on a cash flow basis.
What is the price target of Bio-Techne Corp (TECH)?
The 12-month analyst consensus target is $70.73, about 1.9% below the current $72.12. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Bio-Techne Corp (TECH)?
Our DCF model estimates intrinsic value at $197.11, a +67.8% margin of safety versus today's $72.12. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Bio-Techne Corp's revenue?
Bio-Techne Corp's trailing twelve-month revenue is $1.22B. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Bio-Techne Corp's Altman Z-Score is 3.83, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio9.33x
ROE5.25%
Beta1.28
50D MA$71.85
200D MA$61.00
Shares out0.16B
Float0.16B
Short ratio—
Avg volume3.3M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—